EN | | | / Search

Modification Ac-Lysine

Catalog Number

Format

Price

pAb-cust-120

20 mg

DISCONTINUED

For many years, Diagenode has acquired a strong and reliable experience in the production of custom epigenetic antibodies, allowing us to become one of the most reliable partner in several EU projects in this field of studies. Following our success in optimizing and developing our epigenetic antibody production procedures we are able to offer this as a custom service to meet your specific research needs.

Characteristics
- Flexibility: you can provide us with your protein or with your own peptide or you can choose our custom peptide design/synthesis/coupling service.
- Support: our team of specialists will provide you with free peptide design and top-level advice and support along your immunisation program.
- High-Quality products: our extended immunisation program will ensure you to get more Ab with higher titer and affinity than any other supplier. Moreover at the end of the program you will receive the purified anti-serum.
- Extension of partnership: If you think that your antibody is proven to be of commercial interest, we will be pleased to consider the opportunity to collaborate.
Documents
Custom Antibody 032010V4 DATASHEET
Datasheet description Download

Publications

How to properly cite our product/service in your work

We strongly recommend using this: Modification Ac-Lysine (Hologic Diagenode Cat# pAb-cust-120). Click here to copy to clipboard.

Using our products or services in your publication? Let us know!

HNF1β drives glutathione (GSH) synthesis underlying intrinsic carboplatin resistance of ovarian clear cell carcinoma (OCCC)
Filipa Lopes-Coelho, Sofia Gouveia-Fernandes, Luís G Gonçalves, Carolina Nunes, Inês Faustino, Fernanda Silva, Ana Félix, Sofia A Pereira, Jacinta Serpa
Chemoresistance to platinum-based antineoplastic agents is a consistent feature among ovarian carcinomas; however, whereas high-grade serous carcinoma (OSC) acquires resistance during chemotherapy, ovarian clear cell carcinoma (OCCC) is intrinsically resistant. The main objective of this study was to explore, in vit...

Events

QMUL Centre for Epigenetics Launch Conference 2025
London, UK
Jun 4, 2025

See all events

Site map | Contact us | Conditions of sales | Conditions of purchase | Privacy policy